OPIOID-EXPRESSING B CELLS SILENCE TUMOR-INFILTRATING NOCICEPTOR NEURONS.

Nociceptor neurons, which transmit pain signals, also regulate immunity by releasing immunomodulatory neuropeptides. In head and neck squamous cell carcinoma (HNSCC) and melanoma, our research has shown that tumor-innervating nociceptors modulate anti-tumor immunity through the release of calcitonin gene-related peptide (CGRP) and its interaction with receptor activity-modifying protein 1 (RAMP1). A retrospective analysis of clinical charts from HNSCC patients revealed that higher pain levels correlated with increased opioid use, perineural invasion, and decreased B-cell infiltration-factors associated with poorer survival outcomes. single-cell RNA sequencing demonstrated that opioid use in HNSCC patients downregulates nociceptin/orphanin FQ (N/OFQ), an endogenous ligand for opioid receptor-like-1 (OPRL1). We identified B cells as the primary source of N/OFQ and observed that high expression of either or correlates with better survival in both melanoma and HNSCC. In a mouse model of oral squamous cell carcinoma (oSCC), we found that nociceptor neurons in tongue tumors overexpress and exhibit severe mechanical pain hypersensitivity. Compared to healthy tissue, oSCC tumors have dense infiltration of nociceptor fibers and N/OFQ-expressing B cells. Pharmacological blockade of reduced HNSCC-induced mechanical pain. In a melanoma mouse model, tumor-innervating neurons also overexpressed , and similar overexpression was observed when DRG neurons were co-cultured with B16F10 cells. Activating OPRL1 reduced tumor size, enhanced cytotoxic T-cell infiltration, and relieved cancer-induced thermal hypersensitivity. In contrast, depleting CD19 B cells or blocking OPRL1 led to increased tumor growth, reduced CD8 T-cell infiltration and cytotoxic potential, exacerbated pain, and elevated CGRP levels. Moreover, we discovered that Ramp1 B cells express , but this expression is suppressed by CGRP. Blocking RAMP1 reduced tumor growth and promoted B-cell expression. Overall, these findings suggest that targeting the N/OFQ and RAMP1 pathways could bolster anti-tumor immunity while simultaneously alleviating cancer-induced pain.